Antiepileptic drugs and hormonal contraceptives in adolescent women with epilepsy

Neurology

Volumn 66, Issue 6 SUPPL. 3, 2006, Pages

  Zupanc, Mary L ^a  

^a CHILDREN S HOSPITAL OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CONTRACEPTIVE AGENT; CYTOCHROME P450; DEMULEN 1 50; DEXTROPROPOXYPHENE; ERYTHROMYCIN; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETIRACETAM; FELBAMATE; FLUOXETINE; GABAPENTIN; GESTAGEN; LAMOTRIGINE; LEVONORGESTREL; LIVER ENZYME; MEDROXYPROGESTERONE ACETATE; MESTRANOL PLUS NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; ORTHO NOVUM 1 50; OVCON 50 28; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; PROGESTERONE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; ZOVIA 1 50; SEX HORMONE;

ADOLESCENT; BIRTH DEFECT; BREAKTHROUGH BLEEDING; DRUG BLOOD LEVEL; ENDOCRINE DISEASE; EPILEPSY; EPILEPTIC DISCHARGE; ESTROGEN METABOLISM; FEMALE; FOOD DRUG INTERACTION; HIGH RISK PATIENT; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LIVER MICROSOME; MENSTRUATION DISORDER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SEIZURE; TERATOGENICITY; DRUG EFFECT; DRUG INTERACTION; MENSTRUAL CYCLE; META ANALYSIS; METABOLISM;

ADOLESCENT; ANTICONVULSANTS; CONTRACEPTIVE AGENTS, FEMALE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; EPILEPSY; FEMALE; GONADAL STEROID HORMONES; HUMANS; MENSTRUAL CYCLE; META-ANALYSIS;

EID: 33645740418     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.66.66_suppl_3.s37     Document Type: Review

References (59)

1. Understand the needs of women with epilepsy, or risk OC failure. Contracept Technol Update 1998;19:109-111.
2. Practice parameter: management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1998;51:944-948.
3. Crawford P, Lee P. Gender difference in management of epilepsy - what women are hearing. Seizure 1999;8:135-139.
4. Herzog AG. Reproductive endocrine considerations and hormonal therapy for women with epilepsy. Epilepsia 1991;32(suppl 6):S27-33.
5. Logsdon-Pokorny VK. Epilepsy in adolescents: hormonal considerations. J Pediatr Adolesc Gynecol 2000;13:9-13.
6. Pack AM, Morrell MJ. Treatment of women with epilepsy. Semin Neurol 2002;22:289-298.
7. Morrell MJ, Flynn KL, Seale CG, et al. Reproductive dysfunction in women with epilepsy: antiepileptic drug effects on sex-steroid hormones. CNS Spectr 2001;6:771-786.
8. Harden CL, Koppel BS, Herzog AG, Nikolov BG, Hauser WA. Seizure frequency is associated with age at menopause in women with epilepsy. Neurology 2003;61:451-455.
9. Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA 1986;256:238-240.
10. Nair DR. Epilepsy. The Cleveland Clinic Medical Index. Published May 29, 2002; reviewed May 4, 2003. Available at: http://www.clevelandclinicmeded.com/ diseasemanagement/neurology/epilepsy/epilepsy_t3.htm. Accessed February 20, 2005.
11. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002;24:91-103.
12. Coulam CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979;20:519-525.
13. McAuley JW, Anderson GD. Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations. Clin Pharmacokinet 2002;41:559-579.
14. Willmore LJ. Clinical pharmacology of new antiepileptic drugs. Neurology 2000;55:S17-24.
15. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004;45(suppl 6):13-18.
16. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-491.
17. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002;16:263-272.
18. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-258.
19. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
20. Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995;36(suppl 5):S8-13.
21. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997;38:317-323.
22. Zahn CA, Morrell MJ, Coffins SD, Labiner DM, Yerby MS. Management issues for women with epilepsy: a review of the literature. Neurology 1998;51:949-956.
23. Trussell J, Hatcher RA, Cates W Jr, Stewart FH, Kost K. Contraceptive failure in the United States: an update. Stud Fam Plann 1990;21:51-54.
24. Haukkamaa M. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment. Contraception 1986;33:559-565.
25. Odlind V, Olsson SE. Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with Norplant implants. Contraception 1986;33:257-261.
26. Shane-McWhorter L, Cerveny JD, MacFarlane LL, Osborn C. Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy. Pharmacotherapy 1998;18:1360-1364.
27. Diamond MP, Greene JW, Thompson JM, VanHooydonk JE, Wentz AC. Interaction of anticonvulsants and oral contraceptives in epileptic adolescents. Contraception 1985;31:623-632.
28. Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, Orme M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990;30:892-896.
29. Lamictal [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2004.
30. Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003;61:570-571.
31. Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001;47:151-154.
32. Beyenburg S, Bauer J, Reuber M. New drugs for the treatment of epilepsy: a practical approach. Postgrad Med J 2004;80:581-587.
33. Leppik IE, Bergey GK, Ramsay RE, et al. Advances in antiepileptic drug treatments. A rational basis for selecting drugs for older patients with epilepsy. Geriatrics 2004;59:14-18, 22-24.
34. Leppik IE. Treatment of epilepsy in 3 specialized populations. Am J Manag Care 2001;7:S221-226.
35. Shorvon SD, Tallis RC, Wallace HK. Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice. J Neurol Neurosurg Psychiatry 2002;72:114-115.
36. Reproductive health: an update. ARHP Clinic Proc 2000:2-16.
37. Cromwell PF, Daley AM, Risser WL. Contraception for adolescents: part one. J Pediatr Health Care 2004;18:149-152.
38. Sanfilippo J, Creatsas G. Pediatric and adolescent gynecology. In: Kubba A, Sanfilippo J, Hampton N, eds. Contraception and office gynecology. London: WB Saunders, 1999:265-281.
39. Rosenberg MJ, Waugh MS, Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J Reprod Med 1995;40:355-360.
40. Potter LS. Oral contraceptive compliance and its role in the effectiveness of the method. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991:195-207.
41. Bell S, Wise L, Cooper-Doyle S, Norsigian J. Birth control. In: The Boston Women's Health Book Collective, eds. Our bodies, ourselves for the new century. New York: Touchstone, 1998:288-340.
42. Depo-Provera [package insert]. New York, NY: Pfizer Inc., 2005.
43. Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:401-410.
44. Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metab Drug Interact 2004;20:195-217.
45. Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004;63:S3-8.
46. Gross RA, Gidal BE, Pack AM. Antiseizure drugs and reduced bone density. Neurology [serial online] 2004;62:E24-E25. Available at: http://www.neurology. org. Accessed May 3, 2005.
47. Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987;33:139-144.
48. Morrell MJ, Sarto GE, Shafer PO, Borda EA, Herzog A, Callanan M. Health issues for women with epilepsy: a descriptive survey to assess knowledge and awareness among healthcare providers. J Womens Health Gend Based Med 2000;9:959-965.
49. Krauss GL, Brandt J, Campbell M, Plate C, Summerfield M. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Neurology 1996;46:1534-1539.
50. Long L, Montouris G. Knowledge of women's issues and epilepsy (KOWIE-II): a survey of health care professionals. Epilepsy Behav 2005;6:90-93.
51. Fairgrieve SD, Jackson M, Jonas P, et al. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 2000;321:674-675.
52. Vessey M, Painter R, Yeates D. Oral contraception and epilepsy: findings in a large cohort study. Contraception 2002;66:77-79.
53. Pack AM, Gidal B, Vazquez B. Bone disease associated with antiepileptic drugs. Cleve Clin J Med 2004;71(suppl 2):S42-48.
54. Centers for Disease Control and Prevention. Folic Acid Now Fact Sheet. Available at: http://www.cdc.gov/doc.do?/id=0900f3ec8000d615. Accessed June 23, 2005.
55. Borgohain R, Bar M, Hayes F, et al. Reproductive endocrine characteristics of women with newly diagnosed or inadequately controlled epilepsy - a preliminary analysis. Epilepsia 2003;44(suppl 9):287. Abstract. Available at: www.aesnet.org/Visitors/AnnualMeeting/Abstracts/dsp _Abstract.cfm? id=4185. Accessed May 11, 2005.
56. West Virginia University, Robert C. Byrd Health Sciences Center. Pregabalin drug review. Available at: http://www.hsc.wvu.edu/sop/wvcdhi/ New%20Drug%20Monographs/pregabalin.htm. Accessed May 2, 2005.
57. Felbatol. In: Drug facts and comparisons®. St Louis: Wolters Kluwer Health 2005:1023-1026.
58. Horn CS, Ater SB, Hurst DL. Carbamazepine-exacerbated epilepsy in children an adolescents. Pediatr Neurol 1986;2:340-345.
59. Hirsch LJ, Weintraub D, Du Y, et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004;63:1022-1026.